Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)

NCT00288431 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Sarcoma

Interventions

DRUG: ridaforolimus
DRUG: Doxorubicin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]